ATI RN
ATI Pharmacology Proctored Exam 2019
1. A client is receiving treatment with bevacizumab. Which of the following findings should the nurse monitor?
- A. Hypertension
- B. Hypokalemia
- C. Hyperglycemia
- D. Hypocalcemia
Correct answer: A
Rationale: Correct Answer: A. Bevacizumab is known to cause hypertension as a common adverse effect. The nurse should closely monitor the client's blood pressure to detect and manage this potential side effect promptly. Choice B, hypokalemia, is not typically associated with bevacizumab treatment. Choice C, hyperglycemia, is not a common adverse effect of bevacizumab. Choice D, hypocalcemia, is not a recognized side effect of bevacizumab.
2. What is the action of Nitroglycerin?
- A. Dilates the Bronchi
- B. Reduces Blood Glucose
- C. Reduces Nausea
- D. Dilates Coronary Arteries
Correct answer: D
Rationale: Nitroglycerin acts by dilating the coronary arteries, leading to increased blood flow and oxygen supply to the heart. This helps in relieving angina symptoms by reducing the heart's workload and improving blood supply to the myocardium. Choices A, B, and C are incorrect because Nitroglycerin's primary action is not related to dilating bronchi, reducing blood glucose, or reducing nausea.
3. Why does a nurse on an oncology unit verify a client's current cumulative lifetime dose of doxorubicin before administering it to a client with breast cancer?
- A. Excessive doxorubicin can result in myelosuppression.
- B. Exceeding the lifetime cumulative dose limit of doxorubicin may lead to extravasation.
- C. An excess amount of doxorubicin can lead to cardiomyopathy.
- D. Exceeding the lifetime cumulative dose limit of doxorubicin may cause red-tinged urine and sweat.
Correct answer: C
Rationale: Verifying the client's current cumulative lifetime dose of doxorubicin is necessary because excessive amounts of the medication can lead to cardiomyopathy, a serious and potentially life-threatening side effect. By monitoring the cumulative dose, healthcare providers can help prevent cardiotoxicity and ensure patient safety during treatment.
4. Which of the following is a potassium-sparing diuretic?
- A. Furosemide
- B. Spironolactone
- C. Hydrochlorothiazide
- D. Bumetanide
Correct answer: B
Rationale: Spironolactone is classified as a potassium-sparing diuretic. It works by antagonizing the aldosterone receptor, leading to potassium retention and sodium excretion. This mechanism makes it a suitable choice for conditions where potassium retention is desired, such as in patients with heart failure or liver cirrhosis. Choices A, C, and D are not potassium-sparing diuretics. Furosemide, hydrochlorothiazide, and bumetanide are loop diuretics and thiazide diuretics, respectively, which promote the excretion of potassium.
5. A client has a new prescription for Ferrous sulfate. Which of the following instructions should the nurse include?
- A. Take this medication with milk.
- B. Take this medication on an empty stomach.
- C. Take this medication before bedtime.
- D. Take this medication with antacids.
Correct answer: B
Rationale: The correct answer is to take Ferrous sulfate on an empty stomach. This medication is best absorbed when taken 1 hour before or 2 hours after meals. Instructing the client to take it with milk, before bedtime, or with antacids can decrease its absorption and effectiveness. Taking it with milk can reduce the absorption of iron due to the calcium in milk. Taking it before bedtime is not necessary and may cause gastrointestinal upset. Taking it with antacids can interfere with the absorption of iron.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access